2. Academic Validation
  3. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry

  • Eur J Med Chem. 2019 May 15:170:55-72. doi: 10.1016/j.ejmech.2019.03.004.
Debasis Das 1,  Jian Hong 2
Affiliations

Affiliations

  • 1 Discovery Chemistry Research, Arromax Pharmatech Co. Ltd., Sangtian Island Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, PR China. Electronic address: debasis.das@arromax.com.
  • 2 Discovery Chemistry Research, Arromax Pharmatech Co. Ltd., Sangtian Island Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, PR China.
PMID: 30878832 DOI: 10.1016/j.ejmech.2019.03.004
Abstract

The 4-aminoquinazoline core is an interesting pharmacophore and its applications in medicinal chemistry are wide spread. The core has been used for making many kinase inhibitors in past few years. Many researcher demonstrated 4-aminoquinazoline derivatives as specific kinase inhibitors, including tyrosine kinase and serine/theronine kinases. A number of Anticancer drugs with 4-aminoquinazoline core are in the market, e.g. gefitinib, erlotinib, afatinib, lapatinib, decomitinib etc. 4-aminoquinazoline derivatives are applied for target specific treatment of lung, breast, colon, prostate cancers. In this review, we discussed the current development of 4-aminoquinazoline derivatives as kinase inhibitors and their uses as Anticancer agents in recent years.

Keywords

Aminoquinazoline; Aurora; EGFR; HER; Inhibitor; Kinase; PI3K; Quinazoline; RET; VEGFR.

Figures